First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects

FL058 is a novel diazabicyclooctane β-lactamase inhibitor. This first-in-human study evaluated the safety, tolerability, and population pharmacokinetic (PK)/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects. The results showed that the ma...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrobial agents and chemotherapy Ročník 68; číslo 1; s. e0133023
Hlavní autoři:	Huang, Zhiwei, Yang, Xinyi, Jin, Yi, Yu, Jicheng, Cao, Guoying, Wang, Jingjing, Hu, Yingying, Dai, Jingyi, Wu, Jufang, Wei, Qiong, Tian, Yan, Yu, Shuyan, Zhu, Xu, Mao, Xiaomeng, Liu, Wei, Liang, Hong, Zheng, Shansong, Ju, Yunfei, Wang, Zenghua, Zhang, Jing, Wu, Xiaojie
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.01.2024
Témata:	Adult Anti-Bacterial Agents - pharmacokinetics beta-Lactamase Inhibitors - adverse effects Healthy Volunteers Humans Infusions, Intravenous Meropenem - pharmacology FL058 β-lactamase inhibitor target attainment analysis first-in-human study safety population pharmacokinetics
ISSN:	1098-6596, 1098-6596
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!